Cargando…

Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL(® )platform

BACKGROUND: The cDNA-mediated Annealing, extension, Selection and Ligation (DASL) assay has become a suitable gene expression profiling system for degraded RNA from paraffin-embedded tissue. We examined assay characteristics and the performance of the DASL 502-gene Cancer Panel(v1 )(1.5K) and 24,526...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinholz, Monica M, Eckel-Passow, Jeanette E, Anderson, S Keith, Asmann, Yan W, Zschunke, Michael A, Oberg, Ann L, McCullough, Ann E, Dueck, Amylou C, Chen, Beiyun, April, Craig S, Wickham-Garcia, Eliza, Jenkins, Robert B, Cunningham, Julie M, Jen, Jin, Perez, Edith A, Fan, Jian-Bing, Lingle, Wilma L
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022545/
https://www.ncbi.nlm.nih.gov/pubmed/21172013
http://dx.doi.org/10.1186/1755-8794-3-60
_version_ 1782196513894563840
author Reinholz, Monica M
Eckel-Passow, Jeanette E
Anderson, S Keith
Asmann, Yan W
Zschunke, Michael A
Oberg, Ann L
McCullough, Ann E
Dueck, Amylou C
Chen, Beiyun
April, Craig S
Wickham-Garcia, Eliza
Jenkins, Robert B
Cunningham, Julie M
Jen, Jin
Perez, Edith A
Fan, Jian-Bing
Lingle, Wilma L
author_facet Reinholz, Monica M
Eckel-Passow, Jeanette E
Anderson, S Keith
Asmann, Yan W
Zschunke, Michael A
Oberg, Ann L
McCullough, Ann E
Dueck, Amylou C
Chen, Beiyun
April, Craig S
Wickham-Garcia, Eliza
Jenkins, Robert B
Cunningham, Julie M
Jen, Jin
Perez, Edith A
Fan, Jian-Bing
Lingle, Wilma L
author_sort Reinholz, Monica M
collection PubMed
description BACKGROUND: The cDNA-mediated Annealing, extension, Selection and Ligation (DASL) assay has become a suitable gene expression profiling system for degraded RNA from paraffin-embedded tissue. We examined assay characteristics and the performance of the DASL 502-gene Cancer Panel(v1 )(1.5K) and 24,526-gene panel (24K) platforms at differentiating nine human epidermal growth factor receptor 2- positive (HER2+) and 11 HER2-negative (HER2-) paraffin-embedded breast tumors. METHODS: Bland-Altman plots and Spearman correlations evaluated intra/inter-panel agreement of normalized expression values. Unequal-variance t-statistics tested for differences in expression levels between HER2 + and HER2 - tumors. Regulatory network analysis was performed using Metacore (GeneGo Inc., St. Joseph, MI). RESULTS: Technical replicate correlations ranged between 0.815-0.956 and 0.986-0.997 for the 1.5K and 24K panels, respectively. Inter-panel correlations of expression values for the common 498 genes across the two panels ranged between 0.485-0.573. Inter-panel correlations of expression values of 17 probes with base-pair sequence matches between the 1.5K and 24K panels ranged between 0.652-0.899. In both panels, erythroblastic leukemia viral oncogene homolog 2 (ERBB2) was the most differentially expressed gene between the HER2 + and HER2 - tumors and seven additional genes had p-values < 0.05 and log2 -fold changes > |0.5| in expression between HER2 + and HER2 - tumors: topoisomerase II alpha (TOP2A), cyclin a2 (CCNA2), v-fos fbj murine osteosarcoma viral oncogene homolog (FOS), wingless-type mmtv integration site family, member 5a (WNT5A), growth factor receptor-bound protein 7 (GRB7), cell division cycle 2 (CDC2), and baculoviral iap repeat-containing protein 5 (BIRC5). The top 52 discriminating probes from the 24K panel are enriched with genes belonging to the regulatory networks centered around v-myc avian myelocytomatosis viral oncogene homolog (MYC), tumor protein p53 (TP53), and estrogen receptor α (ESR1). Network analysis with a two-step extension also showed that the eight discriminating genes common to the 1.5K and 24K panels are functionally linked together through MYC, TP53, and ESR1. CONCLUSIONS: The relative RNA abundance obtained from two highly differing density gene panels are correlated with eight common genes differentiating HER2 + and HER2 - breast tumors. Network analyses demonstrated biological consistency between the 1.5K and 24K gene panels.
format Text
id pubmed-3022545
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30225452011-01-19 Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL(® )platform Reinholz, Monica M Eckel-Passow, Jeanette E Anderson, S Keith Asmann, Yan W Zschunke, Michael A Oberg, Ann L McCullough, Ann E Dueck, Amylou C Chen, Beiyun April, Craig S Wickham-Garcia, Eliza Jenkins, Robert B Cunningham, Julie M Jen, Jin Perez, Edith A Fan, Jian-Bing Lingle, Wilma L BMC Med Genomics Research Article BACKGROUND: The cDNA-mediated Annealing, extension, Selection and Ligation (DASL) assay has become a suitable gene expression profiling system for degraded RNA from paraffin-embedded tissue. We examined assay characteristics and the performance of the DASL 502-gene Cancer Panel(v1 )(1.5K) and 24,526-gene panel (24K) platforms at differentiating nine human epidermal growth factor receptor 2- positive (HER2+) and 11 HER2-negative (HER2-) paraffin-embedded breast tumors. METHODS: Bland-Altman plots and Spearman correlations evaluated intra/inter-panel agreement of normalized expression values. Unequal-variance t-statistics tested for differences in expression levels between HER2 + and HER2 - tumors. Regulatory network analysis was performed using Metacore (GeneGo Inc., St. Joseph, MI). RESULTS: Technical replicate correlations ranged between 0.815-0.956 and 0.986-0.997 for the 1.5K and 24K panels, respectively. Inter-panel correlations of expression values for the common 498 genes across the two panels ranged between 0.485-0.573. Inter-panel correlations of expression values of 17 probes with base-pair sequence matches between the 1.5K and 24K panels ranged between 0.652-0.899. In both panels, erythroblastic leukemia viral oncogene homolog 2 (ERBB2) was the most differentially expressed gene between the HER2 + and HER2 - tumors and seven additional genes had p-values < 0.05 and log2 -fold changes > |0.5| in expression between HER2 + and HER2 - tumors: topoisomerase II alpha (TOP2A), cyclin a2 (CCNA2), v-fos fbj murine osteosarcoma viral oncogene homolog (FOS), wingless-type mmtv integration site family, member 5a (WNT5A), growth factor receptor-bound protein 7 (GRB7), cell division cycle 2 (CDC2), and baculoviral iap repeat-containing protein 5 (BIRC5). The top 52 discriminating probes from the 24K panel are enriched with genes belonging to the regulatory networks centered around v-myc avian myelocytomatosis viral oncogene homolog (MYC), tumor protein p53 (TP53), and estrogen receptor α (ESR1). Network analysis with a two-step extension also showed that the eight discriminating genes common to the 1.5K and 24K panels are functionally linked together through MYC, TP53, and ESR1. CONCLUSIONS: The relative RNA abundance obtained from two highly differing density gene panels are correlated with eight common genes differentiating HER2 + and HER2 - breast tumors. Network analyses demonstrated biological consistency between the 1.5K and 24K gene panels. BioMed Central 2010-12-20 /pmc/articles/PMC3022545/ /pubmed/21172013 http://dx.doi.org/10.1186/1755-8794-3-60 Text en Copyright ©2010 Reinholz et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Reinholz, Monica M
Eckel-Passow, Jeanette E
Anderson, S Keith
Asmann, Yan W
Zschunke, Michael A
Oberg, Ann L
McCullough, Ann E
Dueck, Amylou C
Chen, Beiyun
April, Craig S
Wickham-Garcia, Eliza
Jenkins, Robert B
Cunningham, Julie M
Jen, Jin
Perez, Edith A
Fan, Jian-Bing
Lingle, Wilma L
Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL(® )platform
title Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL(® )platform
title_full Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL(® )platform
title_fullStr Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL(® )platform
title_full_unstemmed Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL(® )platform
title_short Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL(® )platform
title_sort expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the dasl(® )platform
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022545/
https://www.ncbi.nlm.nih.gov/pubmed/21172013
http://dx.doi.org/10.1186/1755-8794-3-60
work_keys_str_mv AT reinholzmonicam expressionprofilingofformalinfixedparaffinembeddedprimarybreasttumorsusingcancerspecificandwholegenomegenepanelsonthedaslplatform
AT eckelpassowjeanettee expressionprofilingofformalinfixedparaffinembeddedprimarybreasttumorsusingcancerspecificandwholegenomegenepanelsonthedaslplatform
AT andersonskeith expressionprofilingofformalinfixedparaffinembeddedprimarybreasttumorsusingcancerspecificandwholegenomegenepanelsonthedaslplatform
AT asmannyanw expressionprofilingofformalinfixedparaffinembeddedprimarybreasttumorsusingcancerspecificandwholegenomegenepanelsonthedaslplatform
AT zschunkemichaela expressionprofilingofformalinfixedparaffinembeddedprimarybreasttumorsusingcancerspecificandwholegenomegenepanelsonthedaslplatform
AT obergannl expressionprofilingofformalinfixedparaffinembeddedprimarybreasttumorsusingcancerspecificandwholegenomegenepanelsonthedaslplatform
AT mcculloughanne expressionprofilingofformalinfixedparaffinembeddedprimarybreasttumorsusingcancerspecificandwholegenomegenepanelsonthedaslplatform
AT dueckamylouc expressionprofilingofformalinfixedparaffinembeddedprimarybreasttumorsusingcancerspecificandwholegenomegenepanelsonthedaslplatform
AT chenbeiyun expressionprofilingofformalinfixedparaffinembeddedprimarybreasttumorsusingcancerspecificandwholegenomegenepanelsonthedaslplatform
AT aprilcraigs expressionprofilingofformalinfixedparaffinembeddedprimarybreasttumorsusingcancerspecificandwholegenomegenepanelsonthedaslplatform
AT wickhamgarciaeliza expressionprofilingofformalinfixedparaffinembeddedprimarybreasttumorsusingcancerspecificandwholegenomegenepanelsonthedaslplatform
AT jenkinsrobertb expressionprofilingofformalinfixedparaffinembeddedprimarybreasttumorsusingcancerspecificandwholegenomegenepanelsonthedaslplatform
AT cunninghamjuliem expressionprofilingofformalinfixedparaffinembeddedprimarybreasttumorsusingcancerspecificandwholegenomegenepanelsonthedaslplatform
AT jenjin expressionprofilingofformalinfixedparaffinembeddedprimarybreasttumorsusingcancerspecificandwholegenomegenepanelsonthedaslplatform
AT perezeditha expressionprofilingofformalinfixedparaffinembeddedprimarybreasttumorsusingcancerspecificandwholegenomegenepanelsonthedaslplatform
AT fanjianbing expressionprofilingofformalinfixedparaffinembeddedprimarybreasttumorsusingcancerspecificandwholegenomegenepanelsonthedaslplatform
AT linglewilmal expressionprofilingofformalinfixedparaffinembeddedprimarybreasttumorsusingcancerspecificandwholegenomegenepanelsonthedaslplatform